Head to Head Survey: Alkermes PLC (ALKS) and The Competition
Alkermes PLC (NASDAQ: ALKS) is one of 196 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Alkermes PLC to similar companies based on the strength of its analyst recommendations, dividends, valuation, risk, earnings, institutional ownership and profitability.
This is a breakdown of recent ratings and target prices for Alkermes PLC and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Alkermes PLC Competitors||464||2211||6107||117||2.66|
Alkermes PLC currently has a consensus price target of $65.14, suggesting a potential upside of 26.49%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 1.96%. Given Alkermes PLC’s higher possible upside, equities research analysts clearly believe Alkermes PLC is more favorable than its peers.
Institutional and Insider Ownership
99.1% of Alkermes PLC shares are owned by institutional investors. Comparatively, 48.5% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 5.3% of Alkermes PLC shares are owned by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk and Volatility
Alkermes PLC has a beta of 2.2, meaning that its stock price is 120% more volatile than the S&P 500. Comparatively, Alkermes PLC’s peers have a beta of 1.63, meaning that their average stock price is 63% more volatile than the S&P 500.
Earnings & Valuation
This table compares Alkermes PLC and its peers revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Alkermes PLC||$804.37 million||-$103.30 million||-40.23|
|Alkermes PLC Competitors||$207.80 million||-$2.20 million||0.00|
Alkermes PLC has higher revenue, but lower earnings than its peers. Alkermes PLC is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Alkermes PLC and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Alkermes PLC Competitors||-3,989.00%||-119.24%||-44.05%|
Alkermes PLC beats its peers on 7 of the 12 factors compared.
Alkermes PLC Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company’s products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company’s product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
Receive News & Stock Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related stocks with our FREE daily email newsletter.